The web article is here. The PDF is online here.
The main focus is on interview responses from 100 leaders in the biopharma industry. Barriers were listed as "unstable legal/regulatory framework" and "lack of access to relevant data." Precision medicine requires more "collaboration expertise" than simple pop-the-pill drug development.
The three lead authors are based in Frankfurt, Dusseldorf, and Berlin. Readers interested in a C-level health system view of precision medicine may enjoy a 4-page interview based report by Intel, here.
